ONS: How do CDK4/6 Inhibitors Work
Overview
Explains the mechanism of action or CDK4/6 inhibitor, a targeted therapy used in the treatment of HR+, HER2- metastatic breast cancer.
Funding for development of this activity was provided by an independent educational grant from Pfizer Inc.
ONS Clinical Practice Resources
Focused content to elevate your practice at the point of care, including toolkits, quick guides, discussion tools, checklists, and clinical updates.
View All Clinical Practice Resources